CJC-1295 (Without DAC) — 5mg | Research Use Only (RUO)

Description

A synthetic analog of growth hormone releasing hormone (GHRH) currently being investigated in controlled laboratory environments for its interaction with GHRH receptor signaling pathways.

For laboratory research use only. Not for human or animal consumption.

OVERVIEW

CJC-1295 without DAC (Drug Affinity Complex) is a modified synthetic peptide studied in preclinical models for its interaction with growth hormone releasing hormone receptors. Laboratory research has examined its receptor binding characteristics, signaling duration, and downstream pathway activation compared to native GHRH sequences under controlled experimental conditions.

The “without DAC” designation indicates the absence of a lysine-linked maleimidopropionic acid moiety, resulting in a shorter signaling window compared to DAC-conjugated variants.

Supplied as a lyophilized powder for analytical and experimental research applications.

PRODUCT SPECIFICATIONS

Compound: CJC-1295 (Without DAC) / Mod GRF 1-29
Quantity: 5 mg per vial
Form: Lyophilized powder
Purity: ≥98%
Storage: -20°C recommended, protect from light
CAS: 863288-34-0

RESEARCH APPLICATIONS

– GHRH receptor binding and activation studies
– Growth hormone pathway signaling research
– DAC vs. non-DAC comparative analysis
– Peptide half-life and degradation modeling

RESEARCH USE ONLY

This product is intended strictly for laboratory research purposes. Not for human consumption. Not for veterinary use. Not for therapeutic or diagnostic applications. Not intended to treat, cure, or prevent any condition. Use is limited to qualified professionals in controlled laboratory environments.

Certificate of Analysis available upon request.